Trials / Completed
CompletedNCT00240552
Fosamprenavir Expanded Access
An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fosamprenavir | |
| DRUG | Telzir® |
Timeline
- Start date
- 2003-07-01
- Completion
- 2005-08-01
- First posted
- 2005-10-18
- Last updated
- 2016-09-12
Locations
12 sites across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00240552. Inclusion in this directory is not an endorsement.